1338P A phase III study comparing BCD-021, a bevacizumab biosimilar, and reference bevacizumab in patients with stage IIIB or IV non-squamous NSCLC

Abstract

BCD-021 (JSC BIOCAD) is a biosimilar of the reference bevacizumab (Avastin®). This study compared the efficacy, safety, pharmacokinetics (PK), and immunogenicity of BCD-021 to BEV in patients with stage IIIB or IV non-squamous non-small cell lung cancer (NSCLC).